Effects of 4-month treatment with glycocalyx dietary supplement on endothelial glycocalyx and vascular function after COVID-19 infection

IF 4.4 3区医学 Q1 MEDICINE, GENERAL & INTERNAL

European Journal of Clinical Investigation Pub Date : 2025-04-24 DOI:10.1111/eci.70058

George Pavlidis, Aikaterini Kountouri, Konstantinos Katogiannis, John Thymis, Panagiota Efstathia Nikolaou, Christina Chania, John Karalis, Gabriella Kostelli, Eleni Michalopoulou, Eleni Katsanaki, John Parissis, Hans Vink, Robert Long, Sotirios Tsiodras, Vaia Lambadiari, Ignatios Ikonomidis

{"title":"Effects of 4-month treatment with glycocalyx dietary supplement on endothelial glycocalyx and vascular function after COVID-19 infection","authors":"George Pavlidis, Aikaterini Kountouri, Konstantinos Katogiannis, John Thymis, Panagiota Efstathia Nikolaou, Christina Chania, John Karalis, Gabriella Kostelli, Eleni Michalopoulou, Eleni Katsanaki, John Parissis, Hans Vink, Robert Long, Sotirios Tsiodras, Vaia Lambadiari, Ignatios Ikonomidis","doi":"10.1111/eci.70058","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Coronavirus disease 2019 (COVID-19) has been associated with impaired endothelial and vascular function. We investigated whether intervention with glycocalyx dietary supplement (GDS), containing glucosamine sulfate and fucoidan, improves endothelial glycocalyx and vascular function after COVID-19 infection.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>Fifty-seven convalescent patients 14 days after mild-to-moderate COVID-19 infection managed in an outpatient setting were randomized to receive GDS (<i>n</i> = 29) or placebo (<i>n</i> = 28) for 4 consecutive months. We measured at baseline and at 4 months: (a) perfused boundary region (PBR) of the sublingual microvessels with a diameter range of 4–25 μm, as a marker of endothelial glycocalyx integrity, (b) pulse wave velocity and augmentation index, (c) coronary flow reserve using Doppler echocardiography, and (d) malondialdehyde and protein carbonyls as oxidative stress markers.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Four months after treatment, patients who received GDS showed a greater reduction in PBR 4–25 μm (−6.8% vs. −1.3%), pulse wave velocity (−13.2% vs. −3%), augmentation index (−28.5% vs. −2.5%), malondialdehyde (−26% vs. −2.9%), protein carbonyls (−31.3% vs. −1%) and a greater increase in coronary flow reserve (12.9% vs. 1.6%) compared to placebo (<i>p</i> < .05). In the GDS group, the reduction in PBR 4–25 μm was associated with the corresponding decrease in pulse wave velocity (<i>r</i> = .31, <i>p</i> = .047), malondialdehyde, and protein carbonyls, as well as with the increase in coronary flow reserve (<i>r</i> = −.59, <i>p</i> = .008) at follow-up. Post-treatment, none of the patients under GDS reported post-COVID symptoms compared to 21.4% of the patients under placebo.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>Four-month treatment with GDS may improve endothelial glycocalyx and vascular function after COVID-19 infection.</p>\n </section>\n \n <section>\n \n <h3> Clinical Trial Registration</h3>\n \n <p>URL: https://www.clinicaltrials.gov. Unique identifier: NCT05185934.</p>\n </section>\n </div>","PeriodicalId":12013,"journal":{"name":"European Journal of Clinical Investigation","volume":"55 7","pages":""},"PeriodicalIF":4.4000,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/eci.70058","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Clinical Investigation","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/eci.70058","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Coronavirus disease 2019 (COVID-19) has been associated with impaired endothelial and vascular function. We investigated whether intervention with glycocalyx dietary supplement (GDS), containing glucosamine sulfate and fucoidan, improves endothelial glycocalyx and vascular function after COVID-19 infection.

Methods

Fifty-seven convalescent patients 14 days after mild-to-moderate COVID-19 infection managed in an outpatient setting were randomized to receive GDS (n = 29) or placebo (n = 28) for 4 consecutive months. We measured at baseline and at 4 months: (a) perfused boundary region (PBR) of the sublingual microvessels with a diameter range of 4–25 μm, as a marker of endothelial glycocalyx integrity, (b) pulse wave velocity and augmentation index, (c) coronary flow reserve using Doppler echocardiography, and (d) malondialdehyde and protein carbonyls as oxidative stress markers.

Results

Four months after treatment, patients who received GDS showed a greater reduction in PBR 4–25 μm (−6.8% vs. −1.3%), pulse wave velocity (−13.2% vs. −3%), augmentation index (−28.5% vs. −2.5%), malondialdehyde (−26% vs. −2.9%), protein carbonyls (−31.3% vs. −1%) and a greater increase in coronary flow reserve (12.9% vs. 1.6%) compared to placebo (p < .05). In the GDS group, the reduction in PBR 4–25 μm was associated with the corresponding decrease in pulse wave velocity (r = .31, p = .047), malondialdehyde, and protein carbonyls, as well as with the increase in coronary flow reserve (r = −.59, p = .008) at follow-up. Post-treatment, none of the patients under GDS reported post-COVID symptoms compared to 21.4% of the patients under placebo.

Conclusion

Four-month treatment with GDS may improve endothelial glycocalyx and vascular function after COVID-19 infection.

Clinical Trial Registration

URL: https://www.clinicaltrials.gov. Unique identifier: NCT05185934.

查看原文本刊更多论文

糖萼膳食补充剂治疗4个月对COVID-19感染后内皮糖萼和血管功能的影响。

背景：2019冠状病毒病（COVID-19）与内皮和血管功能受损有关。我们研究了糖萼膳食补充剂（GDS）的干预是否能改善COVID-19感染后内皮糖萼和血管功能。方法：57例在门诊治疗的轻中度COVID-19感染后14天的恢复期患者随机分为GDS组（n = 29）和安慰剂组（n = 28），连续4个月。我们在基线和4个月时测量：(a)舌下微血管灌注边界区（PBR），直径范围为4-25 μm，作为内皮糖萼完整性的标志，(b)脉搏波速度和增强指数，(c)多普勒超声心动图冠状动脉血流储备，(d)丙二醛和蛋白羰基作为氧化应激标志物。结果：治疗4个月后，与安慰剂相比，接受GDS治疗的患者PBR 4-25 μm （-6.8% vs. -1.3%）、脉搏波速度（-13.2% vs. -3%）、增强指数（-28.5% vs. -2.5%）、丙二醛（-26% vs. -2.9%）、蛋白碳基（-31.3% vs. -1%）和冠状动脉血流储备（12.9% vs. 1.6%）的降低幅度更大(p结论：GDS治疗4个月可改善COVID-19感染后的内皮糖萼和血管功能。临床试验注册：URL: https://www.Clinicaltrials: gov唯一标识符：NCT05185934。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

European Journal of Clinical Investigation 医学-医学：内科

CiteScore

9.50

自引率

3.60%

发文量

192

审稿时长

1 months

期刊介绍： EJCI considers any original contribution from the most sophisticated basic molecular sciences to applied clinical and translational research and evidence-based medicine across a broad range of subspecialties. The EJCI publishes reports of high-quality research that pertain to the genetic, molecular, cellular, or physiological basis of human biology and disease, as well as research that addresses prevalence, diagnosis, course, treatment, and prevention of disease. We are primarily interested in studies directly pertinent to humans, but submission of robust in vitro and animal work is also encouraged. Interdisciplinary work and research using innovative methods and combinations of laboratory, clinical, and epidemiological methodologies and techniques is of great interest to the journal. Several categories of manuscripts (for detailed description see below) are considered: editorials, original articles (also including randomized clinical trials, systematic reviews and meta-analyses), reviews (narrative reviews), opinion articles (including debates, perspectives and commentaries); and letters to the Editor.